Comparative Pharmacology
Head-to-head clinical analysis: LOW OGESTREL 21 versus PIMTREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW OGESTREL 21 versus PIMTREA.
LOW-OGESTREL-21 vs PIMTREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive. Suppresses gonadotropin release (FSH and LH) via estrogen (ethinyl estradiol) and progestin (norgestrel), inhibiting ovulation. Also increases cervical mucus viscosity and alters endometrium.
PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily for 21 days, followed by 7 pill-free days.
Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Norgestrel: 18-28 hours; ethinyl estradiol: 13-27 hours. Steady-state achieved after 5-7 days.
Terminal elimination half-life of 2.5 to 4 hours; prolonged in renal impairment (up to 6–12 hours in severe impairment).
Ethinyl estradiol and norgestrel are excreted primarily as glucuronide and sulfate conjugates in urine (50-60%) and feces (30-40%).
Primarily renal (approximately 70% as unchanged drug), with biliary/fecal excretion accounting for the remainder. Less than 5% metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive